Drone strike reduces Indian‑linked pharmaceutical complex to rubble
New Delhi. A Russian‑controlled unmanned aerial vehicle slammed into the Kusum Group’s manufacturing site in Sumy, Ukraine, collapsing the main production hall, killing an engineer and wounding several staff members. The assault hit the plant repeatedly, razing the engineering wing and prompting an immediate evacuation.
Initial loss estimates hover around Rs 400 crore, though the firm says a comprehensive audit is still pending. With the extent of the destruction, the plant is expected to stay shut for an undefined period.
Indian origins, Ukrainian presence
Kusum Group entered the Ukrainian market in 1994 as a distributor of Indian‑sourced medicines. By 2009 it had erected a full‑scale production complex in Sumy, complementing its 2007 manufacturing hub in India. Today the conglomerate markets more than 50 generic products across Ukraine, Uzbekistan, Kazakhstan and the Philippines, positioning itself as a Ukrainian pharma player with Indian roots.
Operations persisted through war – until now
Despite the ongoing conflict, the Sumy plant continued to supply essential medicines to local and regional patients. The latest drone barrage, however, has forced a complete shutdown and triggered discussions about relocating vulnerable output to the group’s Indian facilities.
Ukrainian President Volodymyr Zelenskyy denounced the strike, confirming that a drone attack targeted the pharmaceutical complex and resulted in a death. The episode highlights the escalating risk to civilian and commercial infrastructure in active war zones.
Broader implications
The loss of the Sumy plant jeopardises the availability of key generic drugs in the region and raises doubts about the robustness of cross‑border supply chains during armed conflict. A thorough post‑incident review will quantify the financial hit and operational setbacks for the Indian‑linked enterprise.
